Regulatory press release6/26/2024, 9:00 AMRedwood Pharma provides a new update regarding divestment of company assets
Press release6/12/2024, 10:00 AMRedwood Pharma provides an update on the process for divesting the company's assets
Press release5/8/2024, 6:30 AMRedwood Pharma's product RP501 attracted a lot of interest at ARVO in Seattle
Press release5/7/2024, 6:30 AMTwo international companies begin due diligence on Redwood Pharma's product RP501 ahead of potential commercial agreements
Press release2/28/2024, 7:30 AMRedwood Pharma's innovative dry eye treatment to be presented at ARVO in Seattle
Regulatory press release11/30/2023, 7:30 AMRedwood Pharma AB (publ) changes Certified Adviser to Carnegie Investment Bank AB (publ)
Press release11/22/2023, 7:30 AMRedwood Pharma to participate in the NLS Days partner conference in Copenhagen
Press release10/19/2023, 9:15 AMRedwood Pharma to participate in the BIO-Europe partnering conference in Munich
Regulatory press release5/31/2023, 9:10 PMRedwood Pharma presents positive results from a clinical study with RP501 against dry eye
Press release3/17/2023, 12:00 PMRedwood Pharma completes recruitment for clinical trial with RP501 for dry eye
Press release1/24/2023, 7:30 AMRedwood Pharma takes important steps towards the commercial production of its dry eye product
Regulatory press release12/15/2022, 4:00 PMRedwood Pharma enters partnership with Nextec medical in preparation for European market clearance of RP501
Press release10/19/2022, 1:18 PMInterview with CEO Martin Vidaeus of Redwood Pharma at BioStock Investor Meeting, Stockholm
Press release10/14/2022, 6:30 AMRedwood Pharma: Streamed video of CEO Martin Vidaeus presenting at Aktieportföljen Live in Stockholm, Sweden on Oct. 11, 2022
Press release10/3/2022, 1:42 PMRedwood Pharma to present at AKTIEPORTFÖLJEN LIVE SVERIGE in Stockholm on 11[th] of Oct. 2022 at 14:45